Technical Analysis and Clinical Applications of Lactate Dehydrogenase
Technical Analysis and Clinical Applications of Lactate Dehydrogenase
Lactate dehydrogenase (LDH, EC 1.1.1.27) is a key redox enzyme catalyzing the terminal, reversible “lactate–pyruvate” step of glycolysis, using NAD⁺/NADH as coenzyme. It is widely distributed in multiple tissues, including myocardium, liver, skeletal muscle, kidney, and red blood cells. When mitochondrial oxidative capacity is limited, or under conditions of high-glucose, rapid cell proliferation, LDH catalyzes the reduction of pyruvate to lactate and regenerates NAD⁺, thereby sustaining continuous glycolytic flux.Under aerobic conditions, lactate can be converted back to pyruvate via LDH and oxidized through the tricarboxylic acid (TCA) cycle in oxidative tissues (e.g., myocardium), consistent with lactate shuttling. In parallel, lactate can be transported to the liver and utilized as a gluconeogenic substrate to regenerate glucose (the Cori cycle).Because LDH is abundantly expressed and represents a prototypical “leakage type” intracellular enzyme, its serum levels and isoenzyme profile are frequently used as auxiliary diagnostic and prognostic markers in myocardial infarction, liver injury, hematologic diseases, tumors, and muscle disorders. In vitro, LDH-release–based cytotoxicity assay kits have become routine tools for drug screening, evaluation of immune-mediated killing, and tissue injury models. LDH thus holds significant value in both basic research and clinical applications.
I. Basic Concepts and Physiological Roles of Lactate Dehydrogenase
1.1 Basic Concept and Catalyzed Reaction
Lactate dehydrogenase belongs to the oxidoreductase class and catalyzes the reversible interconversion between L-lactate and pyruvate, coupled to NAD⁺/NADH redox changes. The reaction is:
L-lactate + NAD⁺ ⇌ pyruvate + NADH + H⁺.
This reaction lies at the terminal step of glycolysis and constitutes a key link between anaerobic glycolysis and aerobic oxidative metabolism. By regulating the dynamic balance between lactate and pyruvate and the NAD⁺/NADH ratio, LDH plays a central role in maintaining cellular energy metabolism, redox homeostasis, and metabolic adaptation.
1.2 Tissue Distribution and Localization
LDH is present in virtually all animal tissues and is particularly abundant in the heart, liver, kidney, skeletal muscle, and red blood cells. Most isoforms exist as soluble cytosolic enzymes. In highly aerobic tissues such as myocardium, LDH tends to favor conversion of lactate to pyruvate to support the TCA cycle and oxidative ATP production. In skeletal muscle, liver, and certain tumors, LDH more often catalyzes the reduction of pyruvate to lactate, helping cells adapt to short-term high workload or hypoxic conditions. Under intact cellular conditions, LDH is confined to the cytosol; upon cell necrosis or marked membrane damage, it leaks into serum or culture supernatants and is therefore regarded as a classic “leakage type” intracellular enzyme.
1.3 Significance in Energy Metabolism and Pathological States
Under anaerobic or hypoxic conditions, glycolysis generates pyruvate that cannot be completely oxidized via the mitochondrial TCA cycle. LDH reduces pyruvate to lactate while oxidizing NADH to NAD⁺, ensuring continuous glycolytic flux and providing basic energy supply. Under aerobic conditions, lactate can be reoxidized to pyruvate and fully metabolized through the TCA cycle, participating in lactate shuttling and recycling. Many tumor cells exhibit enhanced glycolysis and lactate production even under adequate oxygen supply (the Warburg effect), often accompanied by upregulated expression and activity of LDH-A. Clinically, elevated serum LDH and changes in its isoenzyme pattern often indicate tissue injury, hemolysis, or increased tumor burden. However, LDH lacks organ specificity and must be interpreted in combination with other markers.
II. Molecular Structure, Isoenzymes, and Enzymological Properties
2.1 Tetrameric Structure and Subunit Types
LDH is an oligomeric enzyme composed of four subunits. In typical mammalian LDH, each subunit has a molecular mass of approximately 35 kDa (total ~140 kDa). There are two types of subunits: H (heart-type) and M (muscle-type). Although highly homologous in amino acid sequence, they differ in substrate affinity, susceptibility to substrate inhibition, and metabolic adaptation. Different combinations of H and M subunits assemble into tetramers that share similar catalytic functions but display subtle differences in physicochemical properties.
2.2 Isoenzyme Types and Tissue Specificity
The combination of H and M subunits in different stoichiometries generates five classical isoenzymes: LDH₁ (H₄), LDH₂ (H₃M), LDH₃ (H₂M₂), LDH₄ (HM₃), and LDH₅ (M₄). Their distribution is tissue-specific. For example, myocardium and red blood cells predominantly express LDH₁ and LDH₂, better suited for lactate oxidation to pyruvate in aerobic metabolism. Liver and skeletal muscle mainly express LDH₄ and LDH₅, which are advantageous in reducing pyruvate to lactate under hypoxic or high-load conditions, thereby rapidly regenerating NAD⁺. This tissue specificity provides a biochemical basis for localizing lesions such as myocardial infarction, liver injury, and skeletal muscle disease.
2.3 Enzymological Properties and Influencing Factors
(1) Optimum pH and Temperature
The optimum pH of LDH depends on the reaction direction and isoenzyme type. In general, LDH exhibits higher activity under neutral to slightly alkaline conditions. For the lactate-to-pyruvate direction, most LDH isoforms show optimal activity around mildly alkaline pH (e.g., ~pH 8.0). The pyruvate-to-lactate direction is more favorable under neutral or slightly acidic conditions. The optimum temperature is typically 30–40 °C; higher temperatures cause protein conformational disruption and irreversible inactivation, thus temperature control is essential during experiments and assays.
(2) Substrate and Coenzyme Affinity
Isoenzymes composed primarily of H subunits display higher affinity for pyruvate but are more prone to substrate inhibition at high pyruvate concentrations, making them better suited to relatively stable aerobic environments for lactate oxidation. Isoenzymes composed mainly of M subunits are more tolerant to high pyruvate concentrations and are advantageous in conditions of intense glycolysis or local hypoxia, where continuous reduction of pyruvate to lactate is needed. The NAD⁺/NADH ratio not only influences reaction direction but also affects the apparent kinetic parameters of LDH and is an important reflection of cellular redox status.
(3) Inhibitors and Stability Modulation
High concentrations of pyruvate exert substrate inhibition on certain LDH isoenzymes. Organic solvents, heavy metal ions, and denaturants can disrupt higher-order protein structure and reduce activity. In practice, buffered systems, protein stabilizers (e.g., BSA, glycerol), and antioxidants are often added to enzyme solutions or assay reagents to enhance LDH storage stability and assay reproducibility.
III. Catalytic Mechanism and Metabolic Functions
3.1 Mechanism of the Reversible Lactate–Pyruvate Reaction
LDH catalyzes the reversible redox reaction between lactate and pyruvate by transferring electrons and protons via key amino acid residues in its active site. Substrate and coenzyme sequentially enter the active site to form a ternary enzyme–coenzyme–substrate complex, in which hydride transfer and structural interconversion between carbonyl and hydroxyl groups occur, generating NADH or NAD⁺. The reversibility of this reaction allows the direction of flux to adjust flexibly according to the metabolic environment, providing metabolic buffering under varying oxygen supply and energy demands.
3.2 Terminal Node of Glycolysis and Lactate Cycling
Under anaerobic or hypoxic conditions, pyruvate produced by glycolysis cannot be fully oxidized via the mitochondrial TCA cycle. LDH converts pyruvate to lactate, which is then transported via the circulation to the liver, myocardium, and other tissues, where it is reoxidized to pyruvate and enters the TCA cycle, contributing to the lactate–pyruvate–glucose cycle. LDH maintains NAD⁺ regeneration throughout this process, sustaining glycolysis, especially during short-term high-intensity exercise, localized ischemia, and certain disease states.
3.3 Tumor Metabolism and the Warburg Effect
Many tumor cells prefer high glycolytic flux and lactate production even under adequate oxygen supply, a phenomenon known as the Warburg effect. In these cells, LDH—particularly LDH-A—is frequently overexpressed and hyperactive, supporting sustained lactate generation and NAD⁺ regeneration and conferring metabolic advantages for rapid proliferation. Excess lactate also acidifies the tumor microenvironment, impairs immune cell function, and promotes tumor invasion and angiogenesis, making LDH an important focus for tumor metabolism research and a potential target for drug development.
IV. LDH Detection Methods and Technical Principles
4.1 Colorimetric Methods
Classical colorimetric methods for LDH detection typically rely on the lactate-to-pyruvate reaction, in which generated pyruvate reacts with 2,4-dinitrophenylhydrazine to form a dinitrophenylhydrazone derivative that appears brownish-red under alkaline conditions. LDH activity is calculated by measuring absorbance and comparing to standards. Although simple in operation, this approach has relatively low sensitivity and specificity and is easily affected by interfering substances in samples; it is now used mainly for teaching or semi-quantitative analyses.
4.2 UV Spectrophotometry
UV spectrophotometry is the most commonly used method for LDH activity measurement in clinical and laboratory settings. It is based on the principle that NADH, but not NAD⁺, has a characteristic absorbance at 340 nm. Under conditions of substrate excess and defined reaction direction, the linear rate of change in absorbance at 340 nm is monitored over time to calculate LDH activity in the sample. This method is highly sensitive and specific and is readily adapted to automated biochemical analyzers. It is widely used to quantify LDH in serum, plasma, tissue homogenates, and cell lysates.
4.3 Isoenzyme Electrophoresis and Typing
LDH isoenzymes differ in net charge and isoelectric point and can be separated by agarose or polyacrylamide gel electrophoresis. After staining, five bands corresponding to LDH₁ through LDH₅ can be visualized. Analysis of their relative intensities helps infer the tissue origin of injury. For example, in acute myocardial infarction, LDH₁ and LDH₂ increase significantly and may show the “flip” pattern (LDH₁ > LDH₂), whereas LDH₅ is prominently increased in liver or skeletal muscle injury. Although routine clinical use of LDH isoenzyme electrophoresis has declined with the availability of more specific markers, it remains useful in complex differential diagnosis and research.
4.4 LDH-Release Assay and Cytotoxicity Testing
(1) Principle
The LDH-release assay is based on the leakage of cytosolic LDH into culture supernatants upon cell membrane damage. Most assay formats are configured in the lactate + NAD⁺ direction, where LDH converts lactate to pyruvate while generating NADH, and the signal is then coupled to tetrazolium reduction or other chromogenic/fluorogenic readouts. If the assay is configured in the pyruvate + NADH direction (pyruvate reduction to lactate), NADH should be provided as the hydride donor and the coupled readout should be designed accordingly.Measurement of absorbance or fluorescence thus reflects LDH concentration in the supernatant and the extent of cell injury.
(2) Controls and Data Calculation
In cytotoxicity assays, wells are usually set up as follows: blank control (medium plus reagents, no cells), spontaneous release (cells plus solvent control), maximum release (cells treated with lysis buffer to release total LDH), and various treatment groups. Using spontaneous release as baseline and maximum release as 100%, cell death percentage in each treatment is calculated from its absorbance, thereby quantifying effects of drugs, toxins, or physical interventions on membrane integrity.
(3) Advantages and Interfering Factors
The LDH-release assay does not require cell lysis and can be combined with other assays on the same sample. It is sensitive to necrotic and late apoptotic cells and suitable for medium- to high-throughput screening. However, assay readouts can be influenced by culture medium components, serum, phenol red, and the optical or chemical properties of test compounds. Appropriate blanks and controls must be included, and spontaneous cell death should be kept within an acceptable range to ensure reliable data.
V. Clinical Significance of LDH
5.1 Changes in Cardiac Diseases
In acute myocardial infarction, cardiomyocyte necrosis leads to LDH release into the bloodstream. Serum LDH activity begins to rise approximately 12–24 hours after onset, peaks at 48–72 hours, and may remain elevated for 7–14 days. Compared with cardiac-specific markers, LDH rises and declines more slowly and can be used as an adjunct marker in missed early infarction or retrospective assessment of disease course. During myocardial injury, LDH isoenzyme profiles often show increased LDH₁ and LDH₂ and a “flip” (LDH₁ > LDH₂), supporting a cardiac origin of damage.
5.2 Liver and Skeletal Muscle Diseases
In liver diseases such as acute viral hepatitis, cirrhosis, and hepatocellular carcinoma, hepatocellular damage causes elevated serum LDH, with a more pronounced increase in LDH₄ and LDH₅. LDH is usually mildly to moderately elevated in cirrhosis but can be markedly increased in primary or metastatic liver cancer. Skeletal muscle injury and muscular dystrophies also elevate serum LDH, with isoenzyme profiles dominated by LDH₅, which helps differentiate them from cardiac damage patterns.
5.3 Hematologic Disorders and Tumors
In hematologic malignancies such as leukemia and lymphoma, the high proliferation rate and metabolic activity of tumor cells often lead to markedly elevated LDH levels, which can serve as an indirect surrogate for disease activity and tumor burden. In hemolytic anemia, red blood cell destruction releases LDH and elevates its serum level; interpretation in conjunction with other hemolysis markers (e.g., free hemoglobin, indirect bilirubin) helps evaluate the degree of hemolysis. In many solid tumors (e.g., lung cancer, melanoma), elevated LDH frequently indicates high tumor burden or poor prognosis and is incorporated as a reference parameter in some staging and prognostic scoring systems.
5.4 Limitations and Integrated Interpretation
LDH is a non-specific marker of tissue injury, and virtually any pathological process that causes cell necrosis or damage can increase its level. It cannot independently identify the specific organ or etiology. Clinical interpretation must be integrated with history, physical findings, imaging studies, and other specific laboratory markers (e.g., cardiac troponins, aminotransferases, creatine kinase isoenzymes, blood counts). Changes in isoenzyme distribution and dynamic trends further aid in comprehensive assessment.
VI. Applications in Experimental Research
6.1 Drug Toxicity and Cell Injury Assessment
In in vitro drug screening and toxicology, the LDH-release assay is one of the standard methods for evaluating cell membrane damage and necrosis. Changes in supernatant LDH activity under different drug concentrations and treatment durations permit construction of dose–response and time–response relationships. Combined with cell viability assays (e.g., MTT, CCK-8, ATP content), the LDH assay helps distinguish antiproliferative effects from cell death–inducing effects.
6.2 Monitoring Immune Killing and Cell Therapy Efficacy
In cytotoxicity assays involving CTLs, NK cells, or CAR-T cells against tumor targets, LDH release provides a non-radioactive and user-friendly alternative to traditional assays, enabling assessment of target-cell lysis under different effector-to-target ratios and comparison of killing efficiency among constructs, co-stimulation strategies, or combination treatments. By comparing LDH levels in the presence and absence of effector cells, immune-mediated cytotoxicity can be quantitatively evaluated.
6.3 Tissue Injury Models and Metabolic Regulation Studies
In models of ischemia–reperfusion, oxygen–glucose deprivation, or toxin exposure, LDH activity in culture supernatants or perfusates serves as a quantitative indicator of tissue and cellular damage. Used together with morphological assessment, apoptosis markers, and inflammatory cytokine measurements, LDH facilitates evaluation of protective effects of drugs, gene interventions, or physical strategies on tissue injury. In addition, combined analysis of LDH activity with lactate levels, glucose consumption, and oxygen consumption rate allows systematic dissection of LDH roles in metabolic reprogramming and cell fate decisions.
VII. Related Aladdin Products
Catalog No. | Product Name | Category | Source/Application | Recommended Application | Remarks |
Recombinant Lactate Dehydrogenase (LDH) | Recombinant protein | Recombinant LDH | Studies of lactate metabolism, cellular energy metabolism, and glycolysis | Suitable as LDH standard or positive control for in vitro activity assays and inhibitor screening | |
Lactate Dehydrogenase from Staphylococcus | Native enzyme | Staphylococcus-derived LDH | Microbial lactate metabolism, fermentation processes, and metabolic characterization of strains | Applicable to fermentation engineering and industrial strain screening | |
Recombinant L-Lactate Dehydrogenase (L-LDH) | Recombinant protein | Recombinant L-type LDH | Studies of L-lactate production pathways, substrate specificity, and enzyme kinetics | Suitable for investigations of L-LDH catalytic mechanisms and directed evolution/mutant screening | |
Recombinant L-Lactate Dehydrogenase (L-LDH) | Recombinant protein | Recombinant L-type LDH | Metabolic pathway reconstruction, synthetic biology, and biocatalysis | Suitable as a key biocatalyst in enzyme engineering and process optimization | |
Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (DNPH, micro) | Assay kit | LDH-release–based cytotoxicity detection | Evaluation of drug/compound cytotoxicity and assessment of cell injury | Micro DNPH method; easy to use and suitable for routine cell biology experiments | |
Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (WST-8, micro) | Assay kit | LDH-release + WST-8 cytotoxicity assay | High-throughput drug screening and assessment of cell viability and damage | Micro method with high sensitivity; can be combined with CCK-8 and similar assays | |
D-Lactate Dehydrogenase (D-LDH) Activity Assay Kit (DNPH, micro) | Activity assay kit | D-LDH activity measurement | Studies of D-lactate metabolic pathways, stereoselective catalysis, and metabolic engineering | Micro DNPH-based assay suitable for analyzing D-lactate–related enzyme activity changes | |
L-Lactate Dehydrogenase Activity Assay Kit (WST-8) | Activity assay kit | L-LDH activity measurement (WST-8 method) | Quantitative analysis of L-LDH activity and functional evaluation of metabolic pathways | Suitable for small-volume, multi-sample, high-throughput settings |
As a key terminal enzyme of glycolysis and a prototypical leakage-type intracellular enzyme, lactate dehydrogenase has long-standing and stable value in the study of energy metabolism, tumor metabolic reprogramming, and evaluation of tissue injury. In the future, integration of metabolomics, proteomics, and single-cell technologies will enable more refined mapping of LDH expression and activity across distinct cell subsets and tissue microenvironments, and help elucidate its relationships with lactate signaling, the immune microenvironment, and drug sensitivity. In parallel, structure-based development of small-molecule inhibitors and selective modulators targeting LDH isoenzymes and specific subunits (such as LDH-A) is expected to provide new concepts for tumor metabolic intervention and combination therapy strategies. With further standardization of analytical technologies and progress in drug discovery targeting metabolic enzymes, lactate dehydrogenase will continue to serve as an important technical support in basic biological research, disease diagnosis and monitoring, and new drug development.
Aladdin: https://www.aladdinsci.com/